Post-earnings recap
Reported
Thu, Nov 6, 2025
EPS actual
$-0.62
EPS est.
$-0.58
EPS surprise
-5.98%
1-day move
+2.44%
This earnings report indicates that Protagonist Therapeutics is still facing challenges, as reflected in their EPS miss. However, the stock reacted positively, rising 2.44%, possibly due to investor optimism about future operational improvements. The lack of guidance suggests uncertainty about the company's short-term outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.62 | N/A | -5.98% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a cautious outlook, focusing on addressing current challenges. They highlighted their commitment to long-term goals despite short-term setbacks.
Management acknowledged the challenges faced this quarter.
They emphasized ongoing efforts to improve operational efficiency.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—